Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study

Lancet

Volumn 366, Issue 9501, 2005, Pages 1945-1953

  Campbell, Peter J ^a   Scott, Linda M ^a   Buck, Georgina ^b   Wheatley, Keith ^c   East, Clare L ^d   Marsden, Joanne T ^e   Duffy, Audrey ^e   Boyd, Elaine M ^d   Bench, Anthony J ^d   Scott, Mike A ^d   Vassiliou, George S ^d   Milligan, Donald W ^f   Smith, Steve R ^g   Erber, Wendy N ^d   Bareford, David ^h   Wilkins, Bridget S ⁱ   Reilly, John T ^j   Harrison, Claire N ^k   Green, Anthony R ^a,d,l  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^g TORBAY HOSPITAL   (United Kingdom)

^h RUSSELLS HALL HOSPITAL   (United Kingdom)

ⁱ ROYAL VICTORIA INFIRMARY   (United Kingdom)

^j UNIVERSITY OF SHEFFIELD   (United Kingdom)

^k ST THOMAS HOSPITAL   (United Kingdom)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE 2;

ADULT; AGED; ARTICLE; BONE MARROW; CELL COUNT; CLINICAL FEATURE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ERYTHROPOIESIS; FEMALE; GENE MUTATION; GRANULOPOIESIS; HUMAN; HUMAN CELL; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 28244442441     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67785-9     Document Type: Article

References (29)

1. W Dameshek Some speculations on the myeloproliferative syndromes Blood 6 1951 372 375
2. A Tefferi, S Murphy Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management Blood Rev 15 2001 121 131
3. JL Spivak, G Barosi, G Tognoni Chronic myeloproliferative disorders Hematology (Am Soc Hematol Educ Program) 2003 200 224
4. CN Harrison, AR Green Essential thrombocythemia Hematol Oncol Clin North Am 17 2003 1175 1190
5. CN Harrison, RE Gale, SJ Machin, DC Linch A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications Blood 93 1999 417 424
6. N el-Kassar, G Hetet, J Briere, B Grandchamp Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets Blood 89 1997 128 134
7. M Griesshammer, S Klippel, E Strunck PRV-1 mRNA expression discriminates two types of essential thrombocythemia Ann Hematol 83 2004 364 370
8. R Kralovics, AS Buser, SS Teo Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders Blood 102 2003 1869 1871
9. AR Moliterno, WD Hankins, JL Spivak Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera N Engl J Med 338 1998 572 580
10. L Teofili, F Pierconti, A Di Febo The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia Blood 100 2002 714 717
11. J Thiele, HM Kvasnicka Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients Ann Hematol 82 2003 148 152
12. EJ Baxter, LM Scott, PJ Campbell Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 2005 1054 1061
13. C James, V Ugo, JP Le Couedic A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 2005 1144 1148
14. RL Levine, M Wadleigh, J Cools Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 2005 387 397
15. R Kralovics, F Passamonti, AS Buser A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 2005 1779 1790
16. S Murphy, P Peterson, H Iland, J Laszlo Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment Semin Hematol 34 1997 29 39
17. CN Harrison, PJ Campbell, G Buck Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia N Engl J Med 353 2005 33 45
18. BJ Bain, DM Clark, IA Lampert, BS Wilkins Bone Marrow Pathology 3rd edn 2001 Blackwell Publishing London, England
19. J Thiele, HM Kvasnicka, R Zankovich, V Diehl Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis Haematologica 85 2000 1126 1134
20. TC Pearson Evaluation of diagnostic criteria in polycythemia vera Semin Hematol 38 suppl 2 2001 21 24
21. R Simon Confidence intervals for reporting results of clinical trials Ann Intern Med 105 1986 429 435
22. A Cnaan, NM Laird, P Slasor Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data Stat Med 16 1997 2349 2380
23. F Passamonti, D Pietra, L Malabarba Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders Br J Haematol 126 2004 650 656
24. E Antonioli, P Guglielmelli, A Pancrazzi Clinical implications of the JAK2 V617F mutation in essential thrombocythemia Leukemia 19 2005 1847 1849
25. LM Scott, PJ Campbell, EJ Baxter The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the myeloproliferative disorders Blood 106 2005 2920 2921
26. JL Spivak Polycythemia vera: myths, mechanisms, and management Blood 100 2002 4272 4290
27. F Passamonti, E Rumi, E Pungolino Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia Am J Med 117 2004 755 761
28. R Marchioli, G Finazzi, R Landolfi Vascular and neoplastic risk in a large cohort of patients with polycythemia vera J Clin Oncol 23 2005 2224 2232
29. KF Schulz, DA Grimes Multiplicity in randomised trials II: subgroup and interim analyses Lancet 365 2005 1657 1661